| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 取代的烷基胺衍生物、其制备方法、含其的组合物及其用途 | CN02806202.7 | 2002-01-11 | CN1313464C | 2007-05-02 | G·陈; J·亚当斯; J·贝米斯; S·布克; G·蔡; M·克罗汉; L·迪皮特罗; C·多明格兹; D·埃尔鲍姆; J·格尔麦因; S·格伊恩斯-迈尔; M·汉德利; Q·黄; J·L·金; T·-S·金; A·基塞尔约夫; X·欧阳; V·F·帕特尔; L·M·史密斯; M·斯特克; A·塔斯克; N·席; S·徐; C·C·袁 |
| 选定的杂环化合物有效预防和治疗多种疾病，例如血管形成介导性疾病。本发明包括新型化合物、其类似物、前体药物和药学上可接受的衍生物、药用组合物以及预防或治疗多种疾病和其它疾病(包括癌症等)的方法。本发明还涉及制备所述化合物的方法以及可用于所述方法的中间体。 | ||||||
| 2 | SGLT2抑制剂的结晶和非结晶形式 | CN201280052078.7 | 2012-10-30 | CN103889429B | 2016-10-19 | J·P·亨史克; 何孟芬; 陈淑萍; 陈勇发 |
| 本发明提供SGLT2抑制剂的无定形形式和结晶复合物，用作新型物质，特别是药学上可接受的形式。SGLT2抑制剂卡纳格列净的晶型称为CS1型、CS2型、CS3型、CS4型和CS5型。 | ||||||
| 3 | SGLT2抑制剂的结晶和非结晶形式 | CN201280052078.7 | 2012-10-30 | CN103889429A | 2014-06-25 | J·P·亨史克; 何孟芬; 陈淑萍; 陈勇发 |
| 本发明提供SGLT2抑制剂的无定形形式和结晶复合物，用作新型物质，特别是药学上可接受的形式。SGLT2抑制剂卡纳格列净的晶型称为CS1型、CS2型、CS3型、CS4型和CS5型。 | ||||||
| 4 | 取代的烷基胺衍生物和使用方法 | CN02806202.7 | 2002-01-11 | CN1671700A | 2005-09-21 | G·陈; J·亚当斯; J·贝米斯; S·布克; G·蔡; M·克罗汉; L·迪皮特罗; C·多明格兹; D·埃尔鲍姆; J·格尔麦因; S·格伊恩斯-迈尔; M·汉德利; Q·黄; J·L·金; T·-S·金; A·基塞尔约夫; X·欧阳; V·F·帕特尔; L·M·史密斯; M·斯特克; A·塔斯克; N·席; S·徐; C·C·袁 |
| 选定的杂环化合物有效预防和治疗多种疾病，例如血管形成介导性疾病。本发明包括新型化合物、其类似物、前体药物和药学上可接受的衍生物、药用组合物以及预防或治疗多种疾病和其它疾病(包括癌症等)的方法。本发明还涉及制备所述化合物的方法以及可用于所述方法的中间体。 | ||||||
| 5 | MAPK INHIBITORS | US16006308 | 2018-06-12 | US20180289684A1 | 2018-10-11 | Henry Krum; Peter Scammells; Bing Wang; Natalie Vinh; Jamie Simpson; David Chalmers |
| The present invention relates to certain novel substituted thiophene compounds and the finding that they display useful efficacy in the inhibition of the p38α MAPK enzyme. This provides for use of the compounds in various treatment methodologies related to MAPK inhibition, including the treatment of inflammation. | ||||||
| 6 | Substituted alkylamine derivatives and methods of use | US10046681 | 2002-01-10 | US20030125339A1 | 2003-07-03 | Guoqing Chen; Jeffrey Adams; Jean Bemis; Shon Booker; Guolin Cai; Lucian Di Pietro; Celia Dominguez; Daniel Elbaum; Julie Germain; Stephanie Geuns-Meyer; Michael Handley; Qi Huang; Joseph L. Kim; Tae-Seong Kim; Alexander Kiselyov; Xiaohu Ouyang; Vinod F. Patel; Leon M. Smith; Markian Stec; Andrew Tasker; Ning Xi; Shimin Xu; Chester Chenguang Yuan; Michael Croghan |
| Selected heterocyclic compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. | ||||||
| 7 | MAPK INHIBITORS | US15505942 | 2015-08-25 | US20170266173A1 | 2017-09-21 | Henry Krum; Peter Scammells; Bing Wang; Natalie Vinh; Jamie Simpson; David Chalmers |
| The present invention relates to certain novel substituted thiophene compounds and the finding that they display useful efficacy in the inhibition of the p38α MAPK enzyme. This provides for use of the compounds in various treatment methodologies related to MAPK inhibition, including the treatment of inflammation. | ||||||
| 8 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | US13829288 | 2013-03-14 | US20130273004A1 | 2013-10-17 | Guoqing CHEN; Jeffrey A. ADAMS; Jean E. BEMIS; Shon BOOKER; Guolin CAI; Lucian V. DIPIETRO; Celia DOMINGUEZ; Daniel ELBAUM; Julie GERMAIN; Stephanie D. GEUNS-MEYER; Michael K. HANDLEY; Qi HUANG; Joseph L. KIM; Tae-Seong KIM; Alexander S. KISELYOV; Xiaohu OUYANG; Vinod F. PATEL; Leon M. SMITH, II; Markian M. STEC; Andrew TASKER; Ning XI; Shimin XU; Chester YUAN; Michael CROGHAN |
| Selected heterocyclic compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. | ||||||
| 9 | Substituted alkyl amine derivatives and methods of use of it | JP2002565984 | 2002-01-11 | JP2004531484A | 2004-10-14 | アダムズ，ジエフリー; エルバウム，ダニエル; オウヤン，シヤオフー; カイ，クオリン; キセリヨフ，アレクサンダー; キム，ジヨウゼフ・エル; キム，テ−ソン; クローガン，マイケル; ゲウンス−マイヤー，ステフアニー; シー，ニン; シウ，シミン; ジエルマン，ジユリー; ステツク，マーキアン; スミス，レオン・エム; タスカー，アンドリユー; チエン，クオチン; デイピエトロ，ルシアン; ドミンゲス，セリア; パテル，ビノード・エフ; ハンドリー，マイケル; ビーミス，ジーン; ブツカー，シヨーン; ホワン，チー; ユアン，チエスター・チエンクワン |
| 特定の複素環化合物は、血管新生介在疾患などの疾患の予防および治療において有効である。 本発明は、新規化合物、その化合物の類縁体、プロドラッグおよび製薬上許容される誘導体、医薬組成物、ならびに疾患および癌などが関与する他の病気もしくは状態の予防および治療方法を包含するものである。 本発明はさらに、そのような化合物の製造方法、ならびにそのような方法で有用な中間体に関するものでもある。 | ||||||
| 10 | CRYSTALLINE AND NON-CRYSTALLINE FORMS OF SGLT2 INHIBITORS | EP12846707 | 2012-10-30 | EP2773359A4 | 2015-10-21 | HO MENG-FEN; CHEN SHU-PING; CHEN YUNG-FA |
| 11 | ＳＧＬＴ２阻害剤の結晶および非結晶形態 | JP2014537749 | 2012-10-30 | JP2014532639A | 2014-12-08 | ポール ヘンシュケ ジュリアン; メン−フェン ホ; シュ−ピン チェン; ユン−ファ チェン |
| 本発明は、特に、薬学的に許容される形態の新規な材料としてSGLT2阻害剤の非結晶形態および結晶複合体を提供する。SGLT2阻害剤カナグリフロジンの結晶形態を、形態CS1、CS2、CS3、CS4およびCS5と呼ぶ。 | ||||||
| 12 | Substituted alkylamine derivative, and method for using the same | JP2009097317 | 2009-04-13 | JP2009286777A | 2009-12-10 | CHEN GUOQING; ADAMS JEFFREY; BEMIS JEAN; BOOKER SHON; CAI GUOLIN; CROGHAN MICHAEL; DIPIETRO LUCIAN; DOMINGUEZ CELIA; ELBAUM DANIEL; GERMAIN JULIE; GEUNS-MEYER STEPHANIE; HANDLEY MICHAEL; HUANG QI; KIM JOSEPH L; KIM TAE-SEONG; KISELYOV ALEXANDER; OUYANG XIAOHU; PATEL VINOD F; SMITH LEON M; STEC MARKIAN; TASKER ANDREW; XI NING; XU SHIMIN; YUAN CHESTER CHENGUANG |
| <P>PROBLEM TO BE SOLVED: To provide a new pharmaceutical composition for treating cancer and angiogenesis mediated diseases. <P>SOLUTION: The pharmaceutical composition comprises a pharmaceutically acceptable carrier and a compound represented by formula (XI) [wherein, R is a 5- or 6-membered nitrogen-containing heteroaryl or the like; R<SP>1</SP>is a 4- or 6-membered saturated or a partially unsaturated monocyclic heterocycle or the like; R<SP>2</SP>is a hydrogen, a halogen, a 1C-6C alkyl or the like; R<SP>z</SP>is a 1C-2C alkyl or the like; R<SP>4</SP>is a direct bond, a 1C-4C alkyl or the like] or a pharmaceutically acceptable salt of the compound. <P>COPYRIGHT: (C)2010,JPO&INPIT | ||||||
| 13 | Crystalline and non-crystalline forms of SGLT2 inhibitors | US13664380 | 2012-10-30 | US08999941B2 | 2015-04-07 | Julian Paul Henschke; Meng-Fen Ho; Shu-Ping Chen; Yung-Fa Chen |
| The present invention provides amorphous forms and the crystalline complexes of SGLT2 inhibitors as a novel material, in particular in pharmaceutically acceptable form. The crystalline forms of SGLT2 inhibitor canagliflozin are designated as Forms CS1, CS2, CS3, CS4 and CS5. | ||||||
| 14 | Substituted alkylamine derivatives and methods of use | US13297213 | 2011-11-15 | US08642624B2 | 2014-02-04 | Guoqing Chen; Jeffrey A. Adams; Jean E. Bemis; Shon Booker; Guolin Cai; Lucian V. DiPietro; Celia Dominguez; Daniel Elbaum; Julie Germain; Stephanie Geuns-Meyer; Michael K. Handley; Qi Huang; Joseph L. Kim; Tae-Seong Kim; Alexander S. Kiselyov; Xiaohu Ouyang; Vinod F. Patel; Leon M. Smith; Markian M. Stec; Andrew Tasker; Ning Xi; Shimin Xu; Chester Chenguang Yuan; Michael D. Croghan |
| Selected heterocyclic compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. | ||||||
| 15 | CRYSTALLINE AND NON-CRYSTALLINE FORMS OF SGLT2 INHIBITORS | US13664380 | 2012-10-30 | US20130237487A1 | 2013-09-12 | Julian Paul Henschke; Meng-Fen Ho; Shu-Ping Chen; Yung-Fa Chen |
| The present invention provides amorphous forms and the crystalline complexes of SGLT2 inhibitors as a novel material, in particular in pharmaceutically acceptable form. The crystalline forms of SGLT2 inhibitor canagliflozin are designated as Forms CS1, CS2, CS3, CS4 and CS5. | ||||||
| 16 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | US13297213 | 2011-11-15 | US20120065185A1 | 2012-03-15 | Guoqing CHEN; Jeffrey Adams; Jean Bemis; Shon Booker; Guolin Cai; Lucian Di Pietro; Celia Dominguez; Daniel Elbaum; Julie Germain; Stephanie Geuns-Meyer; Michael Handley; Qi Huang; Joseph L. Kim; Tae-Seong Kim; Alexander Kiselyov; Xiaohu Ouyang; Vinod F. Patel; Leon M. Smith; Markian Stec; Andrew Tasker; Ning Xi; Shimin Xu; Chester Chenguang Yuan; Michael Croghan |
| Selected heterocyclic compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. | ||||||
| 17 | Substituted pyridinecarboxamides for the treatment of cancer | US11234713 | 2005-09-23 | US08058445B2 | 2011-11-15 | Andrew Tasker |
| Selected pyridine carboxamide compounds of Formula XI are effective for treatment of diseases and other maladies or conditions involving, cancer and the like. | ||||||
| 18 | Substituted alkylamine derivatives and methods of use | US11234713 | 2005-09-23 | US20060040956A1 | 2006-02-23 | Guoqing Chen; Jeffrey Adams; Jean Bemis; Shon Booker; Guolin Cai; Lucian Di Pietro; Celia Dominguez; Daniel Elbaum; Julie Germain; Stephanie Geuns-Meyer; Michael Handley; Qi Huang; Joseph Kim; Tae-Seong Kim; Alexander Kiselyov; Xiaohu Ouyang; Vinod Patel; Leon Smith; Markian Stec; Andrew Tasker; Ning Xi; Shimin Xu; Chester Yuan; Michael Croghan |
| Selected heterocyclic compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. | ||||||
| 19 | Substituted alkylamine derivatives and methods of use | US10046681 | 2002-01-10 | US06995162B2 | 2006-02-07 | Guoqing Chen; Jeffrey Adams; Jean Bemis; Shon Booker; Guolin Cai; Lucian Di Pietro; Celia Dominguez; Daniel Elbaum; Julie Germain; Stephanie Geuns-Meyer; Michael Handley; Qi Huang; Joseph L. Kim; Tae-Seong Kim; Alexander Kiselyov; Xiaohu Ouyang; Vinod F. Patel; Leon M. Smith; Markian Stec; Andrew Tasker; Ning Xi; Shimin Xu; Chester Chenguang Yuan; Michael Croghan |
| Selected heterocyclic compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. | ||||||
| 20 | Imidazole hydrazone derivatives | US225583 | 1981-01-16 | US4351948A | 1982-09-28 | Peter J. Fellner; Brendan J. Hamill; Paul W. Manley |
| Compounds corresponding to the following general formula: ##STR1## wherein Ar and Ar.sup.1, which may be the same or different, each represents an aromatic radical which may be substituted one or more times by halogen and/or nitro and/or lower alkyl and/or trihalomethyl and/or cyano and/or lower alkoxy and/or di-lower alkyl-amino, the alkyl groups optionally completing a ring optionally incorporating a further heteroatom, and/or lower alkyl sulphonyl;Alk.sup.1 and Alk.sup.2, which may be the same or different, each represents an alkylene group containing from one to eight carbon atoms which may be substituted one or more times by aryl and/or cycloalkyl and/or lower alkyl and if two such alkyl groups are present, they may complete a ring optionally containing a heteroatom and in which imidazole ring may be further substituted; and m represents 0 or 1; provided that not both Ar and Ar.sup.1 represent phenyl; and acid addition salts thereof. Such compounds are prepared by reaction of a compound corresponding to the following general formula: ##STR2## with a compound of the formula:Ar.sup.1 --NH--NH.sub.2The compounds have an anti-fungal activity as well as an antianaerobic and anti-thrombotic activity. | ||||||
QQ群二维码
意见反馈
意见反馈